GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prelude Therapeutics Inc (NAS:PRLD) » Definitions » Operating Margin %

PRLD (Prelude Therapeutics) Operating Margin % : -845.78% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Prelude Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Prelude Therapeutics's Operating Income for the three months ended in Dec. 2024 was $-33.83 Mil. Prelude Therapeutics's Revenue for the three months ended in Dec. 2024 was $4.00 Mil. Therefore, Prelude Therapeutics's Operating Margin % for the quarter that ended in Dec. 2024 was -845.78%.

The historical rank and industry rank for Prelude Therapeutics's Operating Margin % or its related term are showing as below:

PRLD' s Operating Margin % Range Over the Past 10 Years
Min: -1995.91   Med: -1995.91   Max: -1995.91
Current: -1995.91


PRLD's Operating Margin % is ranked worse than
80.68% of 999 companies
in the Biotechnology industry
Industry Median: -143.38 vs PRLD: -1995.91

Prelude Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Prelude Therapeutics's Operating Income for the three months ended in Dec. 2024 was $-33.83 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-139.71 Mil.


Prelude Therapeutics Operating Margin % Historical Data

The historical data trend for Prelude Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prelude Therapeutics Operating Margin % Chart

Prelude Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Margin %
Get a 7-Day Free Trial - - - - -1,995.91

Prelude Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -1,145.87 -845.78

Competitive Comparison of Prelude Therapeutics's Operating Margin %

For the Biotechnology subindustry, Prelude Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prelude Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Prelude Therapeutics's Operating Margin % falls into.


;
;

Prelude Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Prelude Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=-139.714 / 7
=-1,995.91 %

Prelude Therapeutics's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=-33.831 / 4
=-845.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prelude Therapeutics  (NAS:PRLD) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Prelude Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Prelude Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Prelude Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Executives
Krishna Vaddi director, officer: President, CEO C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
Andrew Combs officer: EVP, Head of Chemistry C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
Bryant David Lim officer: Chief Legal Counsel, Corp Sec. C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Laurent Chardonnet officer: Chief Financial Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jane Huang officer: President, CMO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Deborah Morosini officer: EVP, Chief of Clinical Affairs C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
David J Mauro officer: Chief Medical Officer 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Christopher Pierce officer: EVP and Chief of Business Oper C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803